NO20000732L - Kombinasjon av tyrosinkinaseinhibitor og kjemisk kastrasjon for å behandle prostatacancer - Google Patents

Kombinasjon av tyrosinkinaseinhibitor og kjemisk kastrasjon for å behandle prostatacancer

Info

Publication number
NO20000732L
NO20000732L NO20000732A NO20000732A NO20000732L NO 20000732 L NO20000732 L NO 20000732L NO 20000732 A NO20000732 A NO 20000732A NO 20000732 A NO20000732 A NO 20000732A NO 20000732 L NO20000732 L NO 20000732L
Authority
NO
Norway
Prior art keywords
tyrosine kinase
kinase inhibitor
prostate cancer
combination
chemical castration
Prior art date
Application number
NO20000732A
Other languages
English (en)
Other versions
NO325526B1 (no
NO20000732D0 (no
Inventor
Craig A Dionne
John Isaacs
Jeffry L Vaught
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22000842&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20000732(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of NO20000732D0 publication Critical patent/NO20000732D0/no
Publication of NO20000732L publication Critical patent/NO20000732L/no
Publication of NO325526B1 publication Critical patent/NO325526B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20000732A 1997-08-15 2000-02-14 Sammensetning omfattende tyrosinkinaseinhibitor i form av indolokarbazol og et kjemisk kastreringsmiddel, samt anvendelse av disse for fremstilling av et medikament for a behandle prostatacancer. NO325526B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5589197P 1997-08-15 1997-08-15
PCT/US1998/016849 WO1999008668A2 (en) 1997-08-15 1998-08-13 Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer

Publications (3)

Publication Number Publication Date
NO20000732D0 NO20000732D0 (no) 2000-02-14
NO20000732L true NO20000732L (no) 2000-03-28
NO325526B1 NO325526B1 (no) 2008-06-02

Family

ID=22000842

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20000732A NO325526B1 (no) 1997-08-15 2000-02-14 Sammensetning omfattende tyrosinkinaseinhibitor i form av indolokarbazol og et kjemisk kastreringsmiddel, samt anvendelse av disse for fremstilling av et medikament for a behandle prostatacancer.

Country Status (23)

Country Link
US (1) US5985877A (no)
EP (1) EP1011648B2 (no)
JP (1) JP2001515032A (no)
KR (1) KR100612161B1 (no)
CN (1) CN1147317C (no)
AT (1) ATE208210T1 (no)
AU (1) AU737092B2 (no)
BR (1) BR9812122A (no)
CA (1) CA2299471C (no)
CZ (1) CZ297198B6 (no)
DE (1) DE69802422T3 (no)
DK (1) DK1011648T4 (no)
EA (1) EA002525B1 (no)
ES (1) ES2163293T5 (no)
HK (1) HK1028565A1 (no)
HU (1) HUP0003194A3 (no)
NO (1) NO325526B1 (no)
NZ (2) NZ502646A (no)
PL (1) PL193375B1 (no)
PT (1) PT1011648E (no)
TR (1) TR200000415T2 (no)
UA (1) UA61970C2 (no)
WO (1) WO1999008668A2 (no)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2345213A1 (en) * 1998-10-08 2000-04-13 Takeda Chemical Industries, Ltd. Agent that retards transformation of hormone-dependent cancer to non-hormone-dependent cancer
GB0007371D0 (en) * 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
GB0008368D0 (en) * 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
US20020169154A1 (en) * 2001-04-04 2002-11-14 Cephalon, Inc. Novel methods and compositions involving trk tyrosine kinase inhibitors and antineoplastic agents
JP2004528368A (ja) * 2001-05-08 2004-09-16 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 抗ｅｇｆｒ抗体と抗ホルモン剤を用いた組合せ療法
SE0101697D0 (sv) * 2001-05-14 2001-05-14 Astrazeneca Ab Pharmaceutical combination
IL144583A0 (en) 2001-07-26 2002-05-23 Peptor Ltd Chimeric protein kinase inhibitors
JP2003137814A (ja) * 2001-08-10 2003-05-14 Takeda Chem Ind Ltd ＧｎＲＨアゴニストの併用剤
AU2002331720B2 (en) * 2001-08-24 2007-10-11 Johns Hopkins University Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
KR20120035234A (ko) 2003-04-11 2012-04-13 메디뮨 엘엘씨 재조합 ｉｌ?９ 항체 및 그의 용도
US20040224000A1 (en) * 2003-05-05 2004-11-11 Romano Deghenghi Implants for non-radioactive brachytherapy of hormonal-insensitive cancers
IL156429A0 (en) * 2003-06-12 2004-01-04 Peptor Ltd Cell permeable conjugates of peptides for inhibition of protein kinases
CA2536238C (en) 2003-08-18 2015-04-07 Medimmune, Inc. Humanization of antibodies
CA2585717A1 (en) 2004-10-27 2006-05-04 Medimmune Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
AU2006227377B2 (en) 2005-03-18 2013-01-31 Medimmune, Llc Framework-shuffling of antibodies
JP5220594B2 (ja) 2005-06-14 2013-06-26 プロトクス セラピューティックス インコーポレイティッド ポア形成修飾タンパク質を用いて良性前立腺肥大症を治療または予防する方法
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
EA017265B1 (ru) * 2006-02-03 2012-11-30 Имклоун Элэлси Применение антитела imc-a12, которое является ингибитором igf-ir, для лечения рака предстательной железы
US20080021013A1 (en) * 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
MX2009002151A (es) 2006-08-28 2009-07-03 Kirin Pharma Kk Anticuerpos monoclonales humanos especificos para light humano antagonistas.
EP2077859A4 (en) 2007-03-30 2010-11-24 Medimmune Llc ANTIBODY FORMULATION
US20090130195A1 (en) 2007-10-17 2009-05-21 Mildred Acevedo-Duncan Prostate carcinogenesis predictor
WO2012103165A2 (en) 2011-01-26 2012-08-02 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
NZ630363A (en) 2012-07-25 2018-09-28 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
SG11201502757QA (en) 2012-10-09 2015-05-28 Igenica Biotherapeutics Inc Anti-c16orf54 antibodies and methods of use thereof
US10100123B2 (en) 2013-06-06 2018-10-16 Pierre Fabre Medicament Anti-C10orf54 antibodies and uses thereof
KR20160054501A (ko) 2013-08-26 2016-05-16 맵백스 테라퓨틱스, 인코포레이티드 시알릴-루이스 ａ에 대한 사람 항체 코드화 핵산
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2015187811A2 (en) 2014-06-04 2015-12-10 MabVax Therapeutics, Inc. Human monoclonal antibodies to ganglioside gd2
ES2834739T3 (es) 2014-12-11 2021-06-18 Pf Medicament Anticuerpos anti-C10orf54 y utilizaciones de los mismos
PL3265123T3 (pl) 2015-03-03 2023-03-13 Kymab Limited Przeciwciała, zastosowania i sposoby
CN113559279A (zh) 2015-05-29 2021-10-29 纪念斯隆凯特琳癌症中心 使用超小纳米粒子通过铁死亡诱导营养素剥夺癌细胞的细胞死亡的治疗方法
CN108925136B (zh) 2015-12-02 2022-02-01 斯特赛恩斯公司 特异于糖基化的btla（b和t淋巴细胞衰减因子）的抗体
CN114470194A (zh) 2015-12-02 2022-05-13 斯特库伯株式会社 与btn1a1免疫特异性结合的抗体和分子及其治疗用途
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
BR112019024717A2 (pt) 2017-05-25 2020-06-09 Univ Cornell nanopartículas ultrapequenas marcadas com zircônio-89 e métodos das mesmas
AU2018277838A1 (en) 2017-05-31 2019-12-19 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
US20200131266A1 (en) 2017-05-31 2020-04-30 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
JP2020522562A (ja) 2017-06-06 2020-07-30 ストキューブ アンド シーオー．， インコーポレイテッド Ｂｔｎ１ａ１又はｂｔｎ１ａ１リガンドに結合する抗体及び分子を用いて癌を治療する方法
RU2667906C1 (ru) * 2017-09-11 2018-09-25 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Блохина" Минздрава России) Производное класса N-гликозидов индоло[2,3-а]пирроло[3,4-с]карбазол-5,7-дионов - N-{ 12-(β-D-ксилопиранозил)-5,7-диоксо-индоло[2,3-а]пирроло[3,4-с] карбазол-6-ил} пиридин-2-карбоксамид, обладающее цитотоксической и противоопухолевой активностью
WO2019073069A1 (en) 2017-10-13 2019-04-18 Boehringer Ingelheim International Gmbh HUMAN ANTIBODIES AGAINST THOMSEN-NEW ANTIGEN (TN)
MX2021000786A (es) 2018-07-20 2021-06-15 Pf Medicament Receptor para supresor de ig del dominio v de activación de células t (vista).

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659695A (en) † 1985-02-08 1987-04-21 Fernand Labrie Method of treatment of prostate cancer
EP0303697B1 (en) † 1987-03-09 1997-10-01 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance k-252
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
US5516771A (en) * 1993-05-28 1996-05-14 Cephalon, Inc. Use of indolocarbazole derivatives to treat a pathological condition of the prostate
AU2096895A (en) * 1994-03-07 1995-09-25 Sugen, Incorporated Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
SE506019C2 (sv) * 1994-05-17 1997-11-03 Forskarpatent I Linkoeping Ab Ljuskälla av konjugerade polymerer med spänningsstyrd färg samt metod för tillverkning av ljuskällan
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US5475110A (en) * 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
US5594009A (en) † 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
US5591855A (en) * 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
US5650407A (en) * 1995-04-05 1997-07-22 Cephalon, Inc. Selected soluble esters of hydroxyl-containing indolocarbazoles
GB9508538D0 (en) † 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5659407A (en) * 1995-06-06 1997-08-19 Apple Computer, Inc. Method and system for rendering achromatic image data for image output devices
WO1998003505A2 (en) † 1996-07-19 1998-01-29 Takeda Chemical Industries, Ltd. Heterocyclic compounds, their production and use

Also Published As

Publication number Publication date
CN1147317C (zh) 2004-04-28
WO1999008668A3 (en) 1999-04-15
PL338885A1 (en) 2000-11-20
CN1268061A (zh) 2000-09-27
ES2163293T5 (es) 2006-01-16
JP2001515032A (ja) 2001-09-18
ES2163293T3 (es) 2002-01-16
CZ297198B6 (cs) 2006-09-13
EP1011648A2 (en) 2000-06-28
NO325526B1 (no) 2008-06-02
CZ2000469A3 (cs) 2001-08-15
NZ502646A (en) 2002-04-26
PT1011648E (pt) 2002-03-28
KR20010022878A (ko) 2001-03-26
NZ517497A (en) 2004-11-26
AU737092B2 (en) 2001-08-09
HUP0003194A3 (en) 2003-03-28
KR100612161B1 (ko) 2006-08-14
DK1011648T3 (da) 2001-12-27
HK1028565A1 (en) 2001-02-23
US5985877A (en) 1999-11-16
CA2299471A1 (en) 1999-02-25
CA2299471C (en) 2007-12-18
TR200000415T2 (tr) 2000-08-21
DK1011648T4 (da) 2005-10-24
ATE208210T1 (de) 2001-11-15
UA61970C2 (en) 2003-12-15
BR9812122A (pt) 2000-07-18
AU9019298A (en) 1999-03-08
EP1011648B2 (en) 2005-07-20
NO20000732D0 (no) 2000-02-14
DE69802422T2 (de) 2002-07-11
EA002525B1 (ru) 2002-06-27
HUP0003194A2 (hu) 2001-07-30
DE69802422D1 (de) 2001-12-13
EA200000220A1 (ru) 2000-10-30
DE69802422T3 (de) 2005-12-29
WO1999008668A2 (en) 1999-02-25
PL193375B1 (pl) 2007-02-28
EP1011648B1 (en) 2001-11-07

Similar Documents

Publication Publication Date Title
NO20000732L (no) Kombinasjon av tyrosinkinaseinhibitor og kjemisk kastrasjon for å behandle prostatacancer
AU6045398A (en) Androgen synthesis inhibitors
EP0667769A4 (en) USE OF SPECIFIC ALPHA-1C COMPOUNDS IN THE TREATMENT OF BENIGN PROSTATE HYPERPLASIA.
NZ285159A (en) Treatment of benign prostatic hyperplasia, endometriosis, prostatic carcinoma and obesity by administration of droloxifene
MY121548A (en) Compounds and methods for the treatment of cancer
MY106484A (en) Combination therapy for phophylaxis and/or treatment of benign prostatic hyperplasia.
ATE399007T1 (de) Raf kinase hemmer
MY112949A (en) Benzo-thiaphene estrogen agonists to treat prostatic hyperplasia
ZA952763B (en) Use of alpha-1C specific compounds to treat benign prostatic hyperplasia
AU6083301A (en) Treating eczema and/or psoriasis
IL113024A0 (en) Quinazolinyl-amino derivatives having alfa-antagonist activity
NO20003848D0 (no) FremgangsmÕte ved behandling av folikkulært lymfom ved anvendelse av inhibitorer for lymfotoksin (LT)-veien
RS92304A (en) Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for long-term preservation of acute urinary retention
IL129705A (en) Use of selected benzotriazole derivatives for protecting human and animal skin and hair from the harmful effects of uv radiation
PL329190A1 (en) Antagonists of alpha -adrenergic receptor
CY1111289T1 (el) Συνθεσεις αναστολεων ογκου που περιεχουν νιτροακριδινη
NO962221D0 (no) Anvendelse av dimeticon for behandling av konstipasjon
TR199701613T1 (xx) Selim prostatik hiperplasyan�n tedavisi i�in melatonin agonistleri.
MX9710075A (es) Antagonistas melatonina para el tratamiento en la hiperplasia prostatica benigna.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees